erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
our partners
.
.
.
.
.
of all car-t cell trials registered since 2001, more than half are being conducted in china.
.
.
.
.